Jennifer Amengual, Joe Schroers-Martin, and Samuel Yamshon discuss innovations for managing Epstein-Barr virus-positive (EBV+) posttransplant lymphoproliferative disease (PTLD).
Jennifer Amengual, Joe Schroers-Martin, and Samuel Yamshon discuss innovations for managing Epstein-Barr virus-positive (EBV+) posttransplant lymphoproliferative disease (PTLD).
Jennifer Amengual, Joe Schroers-Martin, and Samuel Yamshon discuss treatment strategies for Epstein-Barr virus-positive (EBV+) posttransplant lymphoproliferative disease (PTLD).
Jennifer Amengual, Joe Schroers-Martin, and Samuel Yamshon discuss treatment strategies for Epstein-Barr virus-positive (EBV+) posttransplant lymphoproliferative disease (PTLD).
Jennifer Amengual, Joe Schroers-Martin, and Samuel Yamshon discuss diagnostic approaches for Epstein-Barr virus-positive (EBV+) posttransplant lymphoproliferative disease (PTLD).
Jennifer Amengual, Joe Schroers-Martin, and Samuel Yamshon discuss diagnostic approaches for Epstein-Barr virus-positive (EBV+) posttransplant lymphoproliferative disease (PTLD).
Jennifer Amengual, Joe Schroers-Martin, and Samuel Yamshon discuss risk factors, signs, and symptoms of Epstein-Barr virus-positive (EBV+) posttransplant lymphoproliferative disease (PTLD).
Jennifer Amengual, Joe Schroers-Martin, and Samuel Yamshon discuss risk factors, signs, and symptoms of Epstein-Barr virus-positive (EBV+) posttransplant lymphoproliferative disease (PTLD).
Jennifer Amengual, Joe Schroers-Martin, and Samuel Yamshon discuss Epstein-Barr virus-positive (EBV+) posttransplant lymphoproliferative disease (PTLD) and its impact on patients.
Jennifer Amengual, Joe Schroers-Martin, and Samuel Yamshon discuss Epstein-Barr virus-positive (EBV+) posttransplant lymphoproliferative disease (PTLD) and its impact on patients.